Industry Experts

Yiyang has over a decade of experience in cell therapy research and manufacture. She is the Senior Director of Analytical Development at Synthekine, leading the effort of developing and optimizing analytical methods for Synthekine's clinical products of cytokine therapeutics and cell therapies.  Before Synthekine, she was the Director of Cell therapy development at Berkeley Lights (BLI),  helping to advance BLI's proprietary Optofluidic single cell technology for in-depth characterization of immune cells and to build an all-in-one Cell Therapy Manufacture System. Prior to BLI, Yiyang led the Molecular Biology and Research team at Eureka Therapeutics to design and build Eureka's ARTEMIS T cell platform for both liquid and solid tumors using traditional and TCR mimic antibody.  We have successfully advanced the anti-CD19 ARTEMIS (for B cell malignancy) and anti-AFP ARTEMIS (for hepatocellular carcinoma) into Phase I clinical trials and three more programs into the IND-ready stage.